1. kirkskraft
2. dwaysche
3. lieselloveszach
4. 4tokoma4tokoma
5. nlanas2sk051p
1.4tokoma4tokoma 02/22/2018
We should be over 40 by now
2.dwaysche 02/21/2018
Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists
3.4tokoma4tokoma 01/09/2018
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet
4.dwaysche 02/22/2018
ADDING MONEY IN THE BANK!
5.kirkskraft 02/22/2018
Will be in the 40 range soon.
6.kirkskraft 04/03/2018
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
7.kirkskraft 03/01/2018
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet
8.nlanas2sk051p 06/19/2018
Acquires 2% royalty rights on global annual net sales of rimegepant and BHV-3500
9.lieselloveszach 03/06/2018
Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
10.kirkskraft 02/22/2018
Exciting news -
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW